Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive declineRik Ossenkoppele, Oskar Hansson, Alexa Pichet Binette et al.|Nature Medicine|2022Cited by 483
Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical SpectrumWillemijn J. Jansen, Lars Frings, Olin Janssen et al.|JAMA Neurology|2022Cited by 281
CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer’s diseaseKanta Horie, Randall J. Bateman, Gemma Salvadó et al.|Nature Medicine|2023Cited by 249
Association of Elevated Amyloid and Tau Positron Emission Tomography Signal With Near-Term Development of Alzheimer Disease Symptoms in Older Adults Without Cognitive ImpairmentCherie Strikwerda‐Brown, Jens C. Pruessner, Diana A. Hobbs et al.|JAMA Neurology|2022Cited by 133
Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer’s diseaseAlexa Pichet Binette, Virginia Lee, Tamie Sather et al.|Nature Communications|2022Cited by 129